SCPP Management for Spinal Cord Injury
(CASPER Trial)
Trial Summary
What is the purpose of this trial?
This multicenter study will enroll 100 patients with acute traumatic cervical and thoracic SCI who have a lumbar intrathecal catheter inserted within 24 hours of their injury. The lumbar intrathecal catheter will be inserted pre-operatively for the measurement of ITP and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between MAP and the ITP. There are two important distinct yet related objectives in this prospective interventional study. 1. Determine the effect of SCPP maintenance β₯ 65 mmHg in acute SCI on neurologic recovery as measured by ASIA Impairment Scale (AIS) grade conversion and motor score improvement. 2. Collect CSF and blood samples for the measurement of neurochemical biomarkers and storage for future biomarker discovery and validation studies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the treatment SCPP Management for Spinal Cord Injury?
Research suggests that managing spinal cord perfusion pressure (SCPP) can improve outcomes in spinal cord injuries by ensuring adequate blood flow to the spinal cord. Studies have shown that techniques like cerebrospinal fluid drainage can help increase SCPP, potentially leading to better recovery after injury.12345
Is SCPP Management safe for humans?
How is SCPP Management treatment different from other treatments for spinal cord injury?
SCPP Management is unique because it focuses on maintaining spinal cord perfusion pressure (SCPP) to improve outcomes after spinal cord injury, rather than just targeting mean arterial pressure (MAP). This approach aims to ensure adequate blood flow to the spinal cord, which is crucial for recovery, and involves techniques like cerebrospinal fluid drainage to optimize pressure.12345
Research Team
Brian Kwon, MD, PhD
Principal Investigator
University of British Columbia, Faculty of Medicine
Eligibility Criteria
This trial is for adults with acute traumatic spinal cord injury from C0 to T12, treated surgically or non-surgically. Participants must have a lumbar intrathecal catheter inserted within 48 hours of injury and an initial blood sample taken within 24 hours. Excluded are those with minor motor injuries (AIS D), sensory-only deficits, penetrating injuries, other major traumas or medical conditions that could affect safety or results.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg with MAP augmentation and CSF drainage
Follow-up
Participants are monitored for neurologic recovery using the ISNCSCI examination at Baseline, Days 1-7, and months 3, 6, and 12
Treatment Details
Interventions
- SCPP Management
SCPP Management is already approved in Canada, United States for the following indications:
- Acute Spinal Cord Injury
- Spinal Paralysis
- Fractured Spine
- Acute Spinal Cord Injury
- Spinal Paralysis
- Fractured Spine
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
Rick Hansen Institute
Collaborator